Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Avantis International Small Cap Value ETF (AVDV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Avantis International Small Cap Value ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.79 (market cap $4.49B), while Avantis International Small Cap Value ETF trades at $102.45. Which is the better fit depends on your goals.
| ACAD | AVDV | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $110.40 |
52-Week Low | $20.06 | $80.02 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AVDV trades at $105.77, up 1.29% today, with a bullish technical signal from moving averages. The ETF focuses on international small-cap value stocks, delivering strong performance with 35% gains highlighted in recent coverage. Dividend payments provide additional investor returns, with the next $1.39 distribution scheduled for June 2026.
Outlook remains positive given international small-cap value momentum, though cyclical sector exposure and reliance on regional factors present risks. Structural alpha concerns noted by analysts suggest monitoring performance drivers beyond broad market trends for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →
